Ipamorelin vs KPV
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Ipamorelin and KPV (also searched as KPV vs Ipamorelin) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Ipamorelin centers on muscle, while KPV leans toward healing. On indexed research, KPV is ahead (Ipamorelin: 4 studies, Preclinical; KPV: 6, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Ipamorelin is strongest for muscle; KPV for healing.
- •Evidence: Ipamorelin Preclinical (4 studies) vs KPV Human evidence (6).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Growth Hormone Secretagogue | Selective GHRP
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
Ipamorelin vs KPV: side-by-side
| Metric | Ipamorelin | KPV |
|---|---|---|
| Class | GH | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Human evidence |
| Studies indexed | 4 | 6 |
| Research level | Well Studied | Emerging |
| Strongest effect | Muscle & body comp | Healing & recovery |
| Healing & recovery | 2.0 | 4.0▲ |
| Muscle & body comp | 4.0▲ | 0.0 |
| Metabolic & appetite | 3.0▲ | 0.0 |
| Neuro & mood | 2.0▲ | 0.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 2.0 | 4.0▲ |
| Skin & aesthetics | 3.0▲ | 2.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Ipamorelin | KPV |
|---|---|---|
| Mechanism | Selective GH secretagogue / ghrelin-receptor agonist | — |
| Route | Subcutaneous injection | — |
| Half-life | ~2 h | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Ipamorelin?
### Summary Ipamorelin is a synthetic peptide that acts as a selective agonist of the growth hormone secretagogue receptor, primarily stimulating growth hormone release. Its potential therapeutic applications are being explored in various contexts, including weight management and pain modulation.
Full Ipamorelin profile, mechanism & studies →What is KPV?
### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.
Full KPV profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | KPV | 4.0/5 effect signal |
| Muscle | Ipamorelin | 4.0/5 effect signal |
| Metabolic | Ipamorelin | 3.0/5 effect signal |
| Neuro | Ipamorelin | 2.0/5 effect signal |
| Sleep | Ipamorelin | 1.0/5 effect signal |
| Inflammation | KPV | 4.0/5 effect signal |
| Skin | Ipamorelin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Ipamorelin and KPV?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Ipamorelin vs KPV: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Ipamorelin has 4 approved studies indexed (Preclinical), and KPV has 6 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Ipamorelin or KPV better?
It depends on your goal. Ipamorelin is strongest for muscle; KPV for healing. KPV has more indexed studies (6). See the goal-by-goal breakdown above.
Is Ipamorelin or KPV better for weight loss?
Ipamorelin shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is Ipamorelin or KPV better for muscle?
Ipamorelin leads on the muscle & body-composition axis (4.0/5).
Which has more research, Ipamorelin or KPV?
Ipamorelin has 4 approved studies indexed (Preclinical); KPV has 6 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Ipamorelin and KPV?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Ipamorelin vs KPV?
Ipamorelin: no community-reported effects logged yet. KPV: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Ipamorelin or KPV FDA-approved?
Ipamorelin is a research-use compound and is not FDA-approved. KPV is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is KPV better than Ipamorelin?
For healing, KPV has the edge; for muscle, Ipamorelin does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Ipamorelin and KPV are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.